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Abacavir is an effective nucleoside analog reverse transcriptase inhibitor used to treat human immunodeficiency virus (HIV) 
infected patients. Its main side effect is hypersensitivity reaction (HSR). The incidence of the HSR is associated with ethnicity 
among patients exposed to abacavir, and retrospective and prospective studies show a significantly increased risk of ab-
acavir-induced HSR in human leukocyte antigen (HLA)-B*57:01-carrying patients. Immunological studies indicated that ab-
acavir interacts specifically with HLA-B*57:01 and changed the binding specificity between the HLA molecule and the 
HLA-presented endogenous peptide repertoire, leading to a systemic autoimmune reaction. HLA-B*57:01 screening, com-
bined with patch testing, had clinically predictive value and cost-effective impact in reducing the incidence of ab-
acavir-induced HSR regardless of the HLA-B*57:01 prevalence in the population. Therefore, the US Food and Drug Admin-
istration (FDA) and international HIV treatment guidelines recommend a routine HLA-B*57:01 screening prior to abacavir 
treatment to decrease false positive diagnosis and prevent abacavir-induced HSR. The studies of abacavir-induced HSR and the 
implementation of the HLA-B*57:01 screening in the clinic represent a successful example of the use of pharmacogenetics for 
personalized diagnosis and therapy. 
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Abacavir is a nucleoside analog reverse transcriptase inhib-
itor that is used in combination with other antiretroviral 
agents to treat human immunodeficiency virus (HIV) in-
fected patients and acquired immunodeficiency syndrome 
(AIDS) patients [13]. Abacavir-induced hypersensitivity 
reaction (HSR) is the main side effect of the drug, which 
can be severe, and in rare cases, fatal [4]. Symptoms of ab-
acavir-induced HSR include fever, skin rash, fatigue, gas-
trointestinal symptoms, and respiratory symptoms. The 
clinical diagnostic criteria for abacavir-induced HSR require 
at least two symptoms of fever, rash, nausea, vomiting, 
headache, lethargy, myalgia, arthralgia or gastrointestinal 
symptoms, occurring within 6 weeks after commencement, 
and resolving within 72 hours after withdrawal, of the drug 
[3,4]. 
1  Abacavir-induced HSR incidence  
Over the last decade, many studies have aimed to determine 
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the risk factors of abacavir-induced HSR, and to develop 
diagnostic methods to identify patients with true ab-
acavir-induced HSR [5]. Epidemiologic analyses of clinical 
trial data revealed that abacavir-induced HSR occurs in 
2.3%9% of patients exposed to abacavir with incidence 
differing by ethnicity [68]. A meta-analysis conducted by 
GlaxoSmithKline (GSK), consisting of 5332 patients ex-
posed to abacavir for at least 24 weeks, showed 197 (3.7%) 
cases of abacavir-induced HSR [9]. In univariate models, 
differences of incidence rate were found within the expected 
range of 3%6%, with the lowest risk of abacavir-induced 
HSR among African-Americans (3% abacavir-induced HSR) 
in comparison to other ethnic groups [9]. Later, to more 
accurately diagnose, report and manage abacavir-induced 
HSR cases, GSK improved the standardized ab-
acavir-induced HSR case report form for all new protocols 
to include more comprehensive information for the syn-
drome, especially the cases with respiratory symptoms. In 
addition, educational materials and the product label were 
updated to increase the awareness of the syndrome among 
patients and healthcare providers. After all these changes, 
an updated retrospective analysis consisting of 8038 expo-
sure patients was conducted. The new reporting rate for 
abacavir-induced HSR was dramatically changed from 
3.6% to 7.6% (p<0.001), resulting in a change of true inci-
dence rate from 3.7% to 5.0% for abacavir-induced HSR 
among all patients [10]. These modifications increased the 
awareness of the syndrome and decreased misclassification 
of the adverse reaction. Notably, the updated study sug-
gested that African Americans have the lowest risk of de-
veloping abacavir-induced HSR after exposure to the drug, 
in comparison to other ethnicities [9,10]. 
2  Prevalence and association of HLA-B*57:01 
with abacavir-induced HSR 
The correlation between ethnicity and the risk of developing 
abacavir-induced HSR indicated that genetic background 
might be involved. In 2001, case reports showed that a 
Caucasian HIV-infected patient and his 9-year-old daughter 
both developed abacavir-induced HSR after abacavir treat-
ment, suggesting some genetic factors of the symptom [11]. 
To identify possible genetic markers that are linked to ab-
acavir-induced HSR, 114 polymorphic loci among 12 gene 
families associated with abacavir metabolism or immune 
responses were selected to perform association studies [12]. 
It was found that abacavir-induced HSR was strongly cor-
related with multiple major histocompatibility complex 
(MHC) markers. Among them, human leukocyte antigen 
(HLA)-B57 had a significant association with ab-
acavir-induced HSR with a sensitivity of 46% (39 of 84 
patients) and an odds ratio of 23.6 (95% CI 8.0100, 
p<0.0001) [12]. Using a high-resolution HLA genotyping 
method, Mallal et al. [13] more finely mapped the risk allele 
associated with abacavir-induced HSR to be the HLA- 
B*57:01, with a sensitivity of 78% (14 of 18 patients with 
abacavir-induced HSR) and an odds ratio of 117 (95% CI 
29481, p<0.0001).  Studies to identify HLA-B*57:01 
prevalence in many different ethnic populations have been 
performed [1232], and are summarized in Table 1. The 
highest prevalence (11%) was found in Indian ethnic groups 
in northern Thailand, while among East Asian populations 
including Chinese, Korean, and Japanese, HLA-B*57:01 
prevalence was relatively low (00.3%). The frequency of 
HLA-B*57:01 in Chinese HIV-infected patients, including 
North Mainland Chinese, Hong Kong Chinese and Taiwan 
Chinese, was reported to be 02% [22,29,32]. Among 534 
Korean and 371 Japanese patients, none had an HLA- 
B*57:01 allele [19,31]. Caucasians in North America, the 
UK, Spain, and Australia have a prevalence of the 
HLA-B*57:01 allele of 6.5%10% [14,26,30]. African 
Americans have a prevalence of 1.1%2.4%, which is 
higher than the 1% seen in sub-Saharan Africans [23,29]. 
Surprisingly, no HLA-B*57:01 alleles were found in 247 
Ugandan HIV-infected patients [25]. 
Progress was rapid in identifying and putting into clinical 
practice the association between HLA-B*57:01 and ab-
acavir-induced HSR. As shown in Table 2, abacavir-   
induced HSR is consistently associated with HLA-B*57:01. 
In 2002, Mallal et al. first described the association between 
HLA-B*57:01 and abacavir-induced HSR in Western Aus-
tralian patients [13]. The allele frequency of HLAB*57:01 
for abacavir-induced HSR patients was 78%, whereas it was 
2% in HSR-free subjects. However, in this study only one 
clinician was taking the responsibility to review patients’ 
records of abacavir treatment history and responses of drug 
reactions, with limited experience in diagnosis/evaluation/ 
classification of abacavir-induced HSR at the time when the 
syndrome was just becoming recognized. Therefore, the 
potential for false diagnosis of abacavir-induced HSR was 
inevitable. At the same time, another case-control study was 
reported by Hetherington et al. [12]. This study included 85 
Table1  Prevalence of HLA-B*57:01 in different populations 
Race/region Frequency (%, n/n) Year (ref.) 
Asian   
North Thailand 11 (n/a) 2003 [26] 
Chinese 0.3 (1/320) 2007 [32] 
Korean 0 (0/534) 2009 [27] 
Japanese 0 (0/371) 2000 [31] 
Caucasian   
Canada 4.1 (20/489) 2012 [15] 
Spain 6.5 (78/1198) 2009 [14] 
Australia 7.7 (20/260) 2006 [30] 
African Descendant   
African American 1.12.4 (n/a) 2003 [26] 
Ugandan 0 (0/247) 2011 [25] 
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Table2  Association of HLA-B*57:01 with abacavir-induced HSR 
Caucasian African Descendant Other Year 
(ref.) Case (n/n) Control (n/n) Case (n/n) Control (n/n) Case (n/n) Control (n/n) 
78% (14/18) 2% (4/167)     2002 [13] 
55% (36/65) 1% (1/80) 0% (0/9) 0% (0/18) 10% (1/10) 0% (0/15) 2002 [12] 
94% (17/18) 2% (4/230)     2004 [21] 
46% (6/13) 10% (5/501)     2004 [18] 
44% (57/13) 4% (8/202) 14% (10/69) <1% (2/206)   2008 [33] 
94% (15/16) 1% (2/307)   100% (3/3) 0% (0/163) 2012 [15] 
 
patients with abacavir-induced HSR (cases) and 115 pa-
tients who were HSR-free after exposure to abacavir treat-
ment for at least 6 weeks (controls). It was found that the 
HLA-B*57:01 allele frequency in abacavir-induced HSR 
patients was much higher than that of HSR-free patients 
(36/65 vs. 1/80, resulting in a sensitivity of 55%). Com-
pared with the Western Australian study [13], this study 
showed a lower sensitivity (55% vs. 78%), indicating that 
the degree of association between the HLA-B* 57:01 allele 
and abacavir-induced HSR varied across different popula-
tions. Martin et al. further explored the association between 
HLA-B*57:01 and abacavir-induced HSR in a larger West-
ern Australian cohort [21], and found that 94.4% (17/18) of 
patients who were clinically diagnosed with abacavir-  
induced HSR carried an HLA-B*57:01 allele while only  
1.7% (4 of 230 subjects) of the HSR-free control group car-
ried it. Compared to their previous study [13], an epicuta-
neous patch test (a well-accepted testing method for diag-
nosis of allergic contact dermatitis) was employed in the 
recent study [21] to make the HSR diagnosis more accurate. 
This significantly increased the HLA-B*57:01 sensitivity of 
detection of abacavir-induced HSR from 78% to 94% in the 
same ethnicity [13,21]. The advantage of the patch test will 
be further discussed below.  
In a more comprehensive study, Hughes et al. [17] per-
formed genetic association studies among Caucasians, Af-
rican Descendants and Hispanics, and results showed that 
HLA-B*57:01 was strongly associated with abacavir-   
induced HSR in Caucasians with a sensitivity of 40%52% 
(p=4.7×1018 in males), depending on the study and analysis 
population. The association was moderate in Hispanics with 
a reduced sensitivity of 20%22% (p=2.1×104). In the Af-
rican Descendant population, however, the association was 
not statistically significant (p=0.27). The lower sensitivity 
in this study might be due to the reasons that more diverse 
population was recruited and patch test was not applied. The 
insignificant association between HLA-B*57:01 and ab-
acavir-induced HSR in African Descendants might be due 
to the relatively small sample size (37 cases and 41 controls) 
in this study. A similar sensitivity was reported among 
Caucasians from the UK [18]. Most recently, the strongest 
association between HLA-B*57:01 and abacavir-induced 
HSR was reported from a southern Alberta based population, 
in which cases are dominantly Caucasians but without de-
tailed stratification with other ethnicities with an odds ratio 
of 6934 (95% CI 321149735) and a sensitivity of 90% (18 
of 20 patients with abacavir-induced HSR) [15]. Saag et al. 
[33] used the patch test for immunological confirmation of 
abacavir-induced HSR and showed 100% sensitivity of 
HLA-B*57:01 as a marker for abacavir-induced HSR in 
both Caucasian and African Descendant populations. Thus, 
there is strong evidence for the risk allele HLA-B*57:01 
being a reliable predictor of abacavir-induced HSR in Cau-
casian patients. In non-Caucasian patients, the reliability of 
this marker is not as robust. This may be because of the 
relatively small samples sizes, and is complicated by the 
relatively low prevalence of the HLA-B*57:01 allele in 
many non-Caucasian ethnic groups (Table 1). The more 
objective measurement of HSR by utilization of the patch 
test appears to improve the reliability of the genetic associa-
tion studies, and suggests that prospective screening for the 
HLA-B*57:01 allele in HIV patients should reduce the in-
cidence of abacavir-induced HSR [3].   
3  Underlying mechanisms of the association 
between HLA-B*57:01 and abacavir-induced 
HSR 
In general, the lack of full understanding of the complex  
interactions among HLA-molecules, antigens, and T-cells 
hinders the understanding of the underlying mechanisms of 
drug-induced hypersensitivities. However, several mecha-
nistic models have been postulated to explain the adverse 
reaction. First, the hapten (or prohapten) theory proposes 
that small molecules (haptens) can bind to a peptide or pro-
tein, thus changing the immunogenicity of the complex. The 
hapten model tries to explain the adverse drug reaction as a 
consequence of the drug (or drug metabolites) binding to 
proteins or peptides, and then the “modified” protein or 
peptide becomes a new antigenic determinant that elicits an 
immune response [34,35]. The second model is the phar-
macological interaction with immune receptors (p-i) model, 
postulating that drugs can directly or reversibly bind to 
T-cell receptors and/or the HLA-peptide complex, trigger-
ing the T-cell mediated immune reactions [36,37]. The third 
model, referred to as the danger model, hypothesizes that 
the major determinant of an immune response by some 
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drugs is whether the drugs cause particular types of cell 
damage. If the drugs cause these types of cell damage, they 
induce immune hypersensitivity reactions [38,39]. Each of 
these models can explain some aspects of the phenomena 
observed in adverse drug reactions; however, complete un-
derstanding remains incomplete, especially for the detailed 
mechanism of the molecular interactions between drugs and 
the immune system.  
The first evidence provided by wet-lab experiments 
showed that the activation of CD8+ cells to produce cyto-
kines was driven by abacavir-HLA-B*57:01 specific bind-
ing [40]. In this study, it was demonstrated that (i) the in-
teraction between HLA molecule and the drug is restricted 
by both the specificity of the HLA-B*57:01 and the 
uniqueness of ligand-abacavir; (ii) abacavir-induced re-
sponses require the activation of conventional HLA-   
antigen-presentation pathway; and (iii) the distinct archi-
tecture of the F-pocket (one of the peptide binding pockets 
for antigen presenting) of the HLA molecule specifies the 
antigen binding affinity.  
On the other hand, based on prior knowledge in pro-
tein-drug interaction and data mining, an in silico approach 
was proposed by Yang et al. [41] to explain the underlying 
mechanisms of adverse drug reactions through specific pro-
tein-drug interactions. By analyzing the binding strength 
and binding conformation changes among 162 drug mole-
cules and 845 proteins, they predicted the specific binding 
interaction between abacavir and HLA-B*57:01 molecule 
(not HLA-B*57:03) mediates skin hypersensitivity. Most 
recently, the mechanism has been further revealed that ab-
acavir selectively interacts with HLA-B*57:01 inducing a 
conformational change which leads to altered binding be-
tween the HLA molecule and the HLA presented endoge-
nous peptide repertoire. Briefly, abacavir binds to the bot-
tom of the antigen-binding cleft in HLA-B*57:01, which 
changes the shape and chemistry of the cleft and leads to 
alterations in the ability to bind the normal repertoire of 
endogenous peptides. Thus, new self-immunological pep-
tides can activate and drive T-cells response, leading to cy-
tokine production that induces an idiosyncratic adverse drug 
reaction [42,43].  
4  Role and benefit of HLA-B*57:01 screening 
The results from association and mechanism studies on the 
interaction between HLA-B*57:01 and abacavir-associated 
HSR imply that HLA-B*57:01 screening has predictive 
value for patients prior to abacavir treatment. To evaluate 
the clinical utility of HLA-B*57:01 screening, a prospective 
study was performed in 260 Western Australia patients [30]. 
This study showed that the incidence of abacavir-induced 
HSR was 2%, and none of the 148 HLA-B*57:01-negative 
patients developed abacavir-related HSR, indicating the 
benefit of HLA-B*57:01 screening for reducing the inci-
dence of HSR [30]. These results were confirmed in the UK 
and France, where the incidence of abacavir-induced HSR 
decreased from 12% to less than 0.5% following introduc-
tion of HLA-B*57:01 screening [44,45]. Therefore, pro-
spective HLA-B*57:01 screening has shown predictive 
benefits for HLA-B*57:01 carrying patients in avoiding 
abacavir-induced HSR. 
Furthermore, studies suggested HLA-B*57:01 screening 
was cost-effective, especially for populations with high 
HLA-B*57:01 prevalence [18,20,4648]. A double-blind 
trial was designed to evaluate the clinical usefulness of 
HLA-B*57:01 screening in Europe and Australia, and in-
cluded 1956 HIV-infected patients [20]. In the study, pa-
tients were randomly divided into two groups: one group 
was assigned to have the routine HLA-B*57:01 screening 
prior to abacavir treatment and only HLA-B*57:01 negative 
patients received abacavir therapy (screening group); the 
other group was assigned to receive abacavir treatment 
without HLA-B*57:01 screening (control group). Patch 
testing was applied in the study to confirm a true HSR di-
agnosis. In the control group, the incidence of ab-
acavir-induced HSR was 2.7%; in contrast, no abacavir- 
induced HSR cases were found in the screening group. 
Combined with patch testing, HLA-B*57:01 screening 
showed an advantage in reducing the incidence of 
HLA-B*57:01-induced HSR, implying its clinical value. 
Studies in Spain and Canada also confirmed the predictive 
value of HLA-B*57:01 screening for HIV-infected patients 
in preventing HSR development [49,50]. 
The cost of abacavir treatment (in combination with other 
drugs) is approximately 15003300 USD per month [15,48] 
and HLA-B*57:01 genotype screening in western countries 
adds a relatively small cost (100 USD) [15,45,48]. However, 
the cost of diagnosis and treatment of a severe HSR ranges 
from 3500 to 30000 USD, depending on the severity level 
[48]. Thus, compared with the cost incurred for treating an 
abacavir-induced HSR, the small incremental cost of geno-
typic screening for the HLA-B*57:01 allele prior to ab-
acavir treatment is dramatically cost-effective 
Prior studies showed that African Descendant and some 
Asian populations have a relatively low frequency of the 
HLA-B*57:01 allele [10,26,27]. In those populations, 
HLA-B*57:01 screening is still useful to decrease false pos-
itive diagnosis of abacavir-induced HSR by combination 
with patch testing. The patch testing was first applied by 
GSK researchers in the study of abacavir-induced HSR [3], 
and has been widely adopted to identify abacavir-induced 
HSR. Several studies have shown that patch testing signifi-
cantly reduced false diagnosis of abacavir-induced HSR 
[21,47,51,52] and strengthened the genotype-phenotype 
association. By combining with patch testing, HLAB*57:01 
screening had 100% sensitivity to predict abacavir-induced 
HSR regardless of race, indicating that such screening could 
be valuable to prevent abacavir-induced HSR even in popu-
lations with low prevalence of HLA-B*57:01 [31,53]. Cur-
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rently, HLA-B*57:01 screening is available in most western 
countries, and international HIV treatment guidelines rec-
ommend routine HLA-B*57:01 screening prior to abacavir 
treatments [4,45]  
5  Summary and perspectives  
Abacavir is an effective anti-retroviral drug for HIV-   
infected patients. The major clinical limitation of abacavir is 
its adverse reaction—hypersensitivity syndrome. Both ret-
rospective and prospective studies showed strong associa-
tion between the HLA-B*57:01 allele and abacavir-induced 
HSR. Mechanistic studies support a novel autoimmunity 
model, in which abacavir alters the self-peptide binding to 
HLA-B*57:01 and leads to autoimmune reactions. As 
summarized in Figure 1, HLA-B*57:01 is a risky allele for 
the development of abacavir-induced HSR. Prospective 
HLA-B*57:01 screening has been shown to prevent ab-
acavir-induced HSR in HIV-infected patients. Accordingly, 
the FDA approved an important safety-related label update 
for abacavir in 2008 that recommends patients be screened 
for the HLA-B*57:01 allele prior to initiating ab-
acavir-containing treatment. HLA-B*57:01 screening rep-
resents a successful example of the application of phar-
macogenetics approaches to the realization of personalized 
medicine. 
Some questions remain, however. For example, why 
don’t all patients with the HLA-B*59:01 allele get ab-
acavir-induced HSR? The incidence of abacavir-induced 
HSR is approximately 60% in HLA-B*57:01 carriers, so 
what are the other risk-modifying factors? Does any other 
variability play a role in the development of the drug ad-
verse reaction? Given the fact that many biological compo-
nents, such as T-cell receptors and drug metabolizing en-
zymes, are also involved in the hypersensitivity reactions, 
other genetic markers (as well as non-genetic factors) may 
be associated with abacavir-induced HSR. Together with 
the HLA-B*57:01 allele, such biomarkers will provide bet-
ter predictive information for the safe use of this drug. 
Next-generation sequencing (NGS) is fundamentally 
changing the way in which genomic information of indi-
viduals at the DNA and RNA level is being studied, and 
enables a better understanding of human genetics to em-  
 
 
Figure 1  HLA-B*57:01 is a risky allele for the development of ab-
acavir-induced HSR. 
power personalized medicine [54,55]. The revolutionary 
power of NGS enables higher sensitivity in detecting genet-
ic variants with more specificity and capability, providing 
enormous opportunities and potential for researchers work-
ing in medicine, biology and life sciences. Along with the 
development of robust informatics tools for nucleotide var-
iant detection, in silico molecular modeling approaches 
should help us better understand and predict interactions 
between specific drugs and HLA variant proteins. Thus, the 
combined approaches of genetic association studies, wet-lab 
mechanistic experiments, and molecular modeling promise 
to answer these questions and lead to the reduction of 
drug-induced adverse reactions. 
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